Holen Sie sich die Stockscreener-App
18.81
3.09%
-0.60
Handel nachbörslich:
18.81
Schlusskurs vom Vortag:
$19.41
Offen:
$19.51
24-Stunden-Volumen:
1.33M
Relative Volume:
2.20
Marktkapitalisierung:
$829.39M
Einnahmen:
$720.53M
Nettoeinkommen (Verlust:
$79.23M
KGV:
11.30
EPS:
1.6648
Netto-Cashflow:
$132.94M
1W Leistung:
-8.38%
1M Leistung:
+9.36%
6M Leistung:
-29.02%
1J Leistung:
-25.77%
1-Tages-Spanne:
$18.70
$19.66
1-Wochen-Bereich:
$18.70
$20.55
52-Wochen-Spanne:
$16.64
$31.26
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Firmenname
Amphastar Pharmaceuticals Inc
Sektor
Telefon
909-980-9484
Adresse
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Compare AMPH vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
18.81 | 829.39M | 720.53M | 79.23M | 132.94M | 1.6648 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-08-12 | Hochstufung | Needham | Hold → Buy |
| 2025-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-11-22 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-03-05 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-17 | Eingeleitet | BofA Securities | Neutral |
| 2023-07-25 | Fortgesetzt | Jefferies | Buy |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-07-29 | Eingeleitet | CapitalOne | Overweight |
| 2022-01-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-05 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-05-01 | Eingeleitet | Northland Capital | Outperform |
| 2019-03-13 | Herabstufung | Needham | Buy → Hold |
| 2019-03-13 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-03-13 | Bestätigt | Needham | Buy |
| 2017-12-01 | Bestätigt | Needham | Buy |
| 2017-11-09 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2017-09-27 | Bestätigt | Needham | Buy |
| 2017-03-14 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2016-08-09 | Bestätigt | Needham | Buy |
| 2016-05-10 | Bestätigt | Needham | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2015-06-19 | Bestätigt | Needham | Buy |
| 2015-06-03 | Eingeleitet | Raymond James | Strong Buy |
| 2014-07-21 | Eingeleitet | Needham | Buy |
Alle ansehen
Amphastar Pharmaceuticals Inc Aktie (AMPH) Neueste Nachrichten
Amphastar Pharmaceuticals Inc (AMPH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Amphastar Pharmaceuticals Inc (AMPH) Institutional Confidence - TradingKey
Amphastar Pharmaceuticals Inc - TradingKey
Amphastar Pharmaceuticals Inc (AMPH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Amphastar Pharmaceuticals Inc (AMPH) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Amphastar Pharmaceuticals Inc (AMPH) Valuation: PE, PB & Fair Value Analysis - TradingKey
Amphastar Pharmaceuticals Inc (AMPH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Amphastar Pharmaceuticals Inc (AMPH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Amphastar Pharmaceuticals (AMPH) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin Amid Challenging QuarterFull Year Guidance - newsline.com
(AMPH) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Healthcare Stock Picks: RadNet and Amphastar to Sell, One Stock to Watch | June 2026News and Statistics - IndexBox
Amphastar Pharmaceuticals pivots to proprietary drugs, biosimilars for growth - MSN
Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth - MarketBeat
How The Investment Story For Amphastar Pharmaceuticals (AMPH) Is Evolving Without New Valuation Shifts - Yahoo Finance
Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged - GlobeNewswire
Amphastar Pharmaceuticals sees generic Atrovent fueling 2026 growth despite BAQSIMI drag - MSN
Barclays Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $20 - Moomoo
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag - MarketBeat
Amphastar (AMPH) director awarded RSUs and options with tax withholding update - Stock Titan
Amphastar Pharmaceuticals (AMPH) director receives RSUs and options grant - Stock Titan
Deflin Gayle awarded RSUs and stock options at Amphastar (NASDAQ: AMPH) - Stock Titan
Amphastar (AMPH) director Diane Gerst receives RSUs and stock option grant - Stock Titan
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Amphastar (AMPH) holders approve directors, EY auditor and annual say-on-pay - Stock Titan
(AMPH) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty - Yahoo Finance
Amphastar (AMPH) Q1 2026 Earnings Transcript - AOL.com
Amphastar Pharmaceuticals (AMPH) Gains 1.4% as Stock Tests Resistance Near $20.34Retail Sentiment - newsline.com
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference - ACCESS Newswire
Amphastar Pharmaceuticals (AMPH) Q1 2026 Earnings: Significant EPS Miss Fails to Dampen Stock Sentiment - newsline.com
(AMPH) Risk Channels and Responsive Allocation - Stock Traders Daily
Amphastar Pharmaceuticals (AMPH) Shows Modest Gains as Stock Hovers Near Key ResistanceQuality Factor - The Legal Advocate
Why Wells Fargo Lowered Amphastar Pharmaceuticals, Inc. (AMPH) Price Target to $19 - Insider Monkey
Amphastar Earnings Call Balances Growth and Margin Strain - TipRanks
Has Amphastar Pharmaceuticals Bottomed Out After Its Steep Decline - Kavout
8 Best Small Cap Pharma Stocks to Buy Right Now - Insider Monkey
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Lower Today - Yahoo Finance
Amphastar forecasts BAQSIMI revenue flat to up low single digits, with 3% list price increase - MSN
Amphastar Pharmaceuticals Q1 2026: Revenue Miss and Pricing Pressures on BAQSIMI - IndexBox
The 5 Most Interesting Analyst Questions From Amphastar Pharmaceuticals’s Q1 Earnings Call - Yahoo Finance
Pharma Earnings Season 2026: Amphastar Flat, Eli Lilly Surges in Q1News and Statistics - IndexBox
Q1 Earnings Roundup: Amphastar Pharmaceuticals (NASDAQ:AMPH) And The Rest Of The Pharmaceuticals Segment - Yahoo Finance
There May Be Some Bright Spots In Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings - simplywall.st
Amphastar Pharmaceuticals' (NASDAQ:AMPH) Conservative Accounting Might Explain Soft Earnings - Yahoo Finance
This Whirlpool Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Sahm
Wells Fargo Initiates Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Announces Target Price $19 - Moomoo
Is Amphastar Pharmaceuticals Inc (AMPH) a Bargain After 5.6% Dro - GuruFocus
Amphastar Shares Fall After Wells Fargo Downgrade - Moomoo
Amphastar Pharmaceuticals tackles BAQSIMI discount pressure, keeps sales outlook - MSN
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook - MarketBeat
AMPH: Proprietary and biosimilar pipeline expansion drives growth, anchored by BAQSIMI® and Primatene MIST - TradingView
Finanzdaten der Amphastar Pharmaceuticals Inc-Aktie (AMPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
11.23%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):